{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:56:24Z","timestamp":1785761784349,"version":"3.56.0"},"reference-count":91,"publisher":"Informa UK Limited","issue":"9","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2026,7,29]]},"DOI":"10.1080\/10428194.2026.2674818","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:53:03Z","timestamp":1779889983000},"page":"1860-1876","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Emerging drug profile: menin inhibitors in NPM1-mutated and KM2A-rearranged acute myeloid leukemia"],"prefix":"10.1080","volume":"67","author":[{"given":"Gaurav","family":"Agarwal","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Panipat Institute of Engineering and Technology","place":["Samalkha, Panipat, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv Kumar","family":"Tonk","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, SPS, Delhi Pharmaceutical Sciences and Research University","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2798-1690","authenticated-orcid":false,"given":"Kavita","family":"Sangwan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Panipat Institute of Engineering and Technology","place":["Samalkha, Panipat, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/GO.23.00229"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-868752"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1301689"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516192"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-2168"},{"key":"e_1_3_3_7_1","unstructured":"NIH. Cancer stat facts: leukemia\u2014acute myeloid leukemia (AML): National Cancer Institute; 2025 [cited 2025 Apr 1]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html."},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30060395"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31041-9"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.2208"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025409"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0257-z"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17162710"},{"issue":"6","key":"e_1_3_3_15_1","first-page":"1470","article-title":"Nucleolar phosphoproteins of normal rat liver and Novikoff hepatoma ascites cells","volume":"35","author":"Kang YJ","year":"1975","unstructured":"Kang YJ, Olson MO, Jones C, et\u00a0al. Nucleolar phosphoproteins of normal rat liver and Novikoff hepatoma ascites cells. Cancer Res. 1975;35(6):1470\u20131475.","journal-title":"Cancer Res"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1987.tb02447.x"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(89)90241-9"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004226"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.08.005"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05812-3"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.6"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026232"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.282621"},{"key":"e_1_3_3_24_1","unstructured":"FDA approves ziftomenib for relapsed or refractory acute myeloid leukemia with a NPM1 mutation; 2026 [cited 2026 Mar 13]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ziftomenib-relapsed-or-refractory acute-myeloid-leukemia-npm1-mutation."},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025028357"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18040637"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/diseases13070227"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022480"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16223743"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.32604\/or.2025.072443"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-02877-y"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-429274"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/17501911.2025.2485019"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2026.118641"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-04752-9"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00826"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104783"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27625"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines14010219"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-20-0679"},{"issue":"1","key":"e_1_3_3_41_1","first-page":"e104","article-title":"Safety and activity of revumenib in combination with fludarabine\/cytarabine (FLA) in patients with relapsed\/refractory acute leukemias","volume":"8","author":"Shukla N","year":"2024","unstructured":"Shukla N, Guest E, Tasian SK, et\u00a0al. Safety and activity of revumenib in combination with fludarabine\/cytarabine (FLA) in patients with relapsed\/refractory acute leukemias. Hemasphere. 2024;8(S1):e104.","journal-title":"Hemasphere"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-192042"},{"key":"e_1_3_3_43_1","unstructured":"GlobeNewswire. Syndax announces FDA approval of Revuforj\u00ae (Revumenib) in adult and pediatric patients with relapsed or refractory NPM1 mutated acute myeloid leukemia; 2025 [cited 2025 Mar 4]. Available from: https:\/\/ir.syndax.com\/news-releases\/news-release details\/syndax-announces-fda-approval-revuforjr-revumenib-adult-and."},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-25-0091"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00914"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1089-8"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009008"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-021-00277-w"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010563"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34780"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008625"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-204375.38648571"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00386-3"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000673"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-167412"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01694"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199170"},{"key":"e_1_3_3_59_1","volume-title":"Abstract 4159213. In Proceedings of the EHA 2025 Congress","author":"Erba H","year":"2025","unstructured":"Erba H, Wang E, Fathi A, et\u00a0al. Ziftomenib combined with intensive induction (7\u2009+\u20093) in newly diagnosed NPM1-M or KMT2A-R acute myeloid leukemia: interim phase 1a results from KOMET-007. Abstract 4159213. In Proceedings of the EHA 2025 Congress, Milan, Italy, 12\u201315 June 2025. EHA Library: Milan, Italy; 2025."},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-190475"},{"key":"e_1_3_3_61_1","unstructured":"Wahner A. Ziftomenib monotherapy shows promise in relapsed\/refractory NPM1-mutant AML. Safety and tolerability of ziftomenib combinations in patients with relapsed\/refractory acute myeloid leukemia [cited 2026 Jan 4]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06001788."},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-207106"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-5199"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-207072"},{"key":"e_1_3_3_65_1","unstructured":"Janssen Research & Development LLC. A study of bleximenib venetoclax and azacitidine for treatment of participants with newly diagnosed acute myeloid leukemia (AML) (cAMeLot-2); 2026 [cited 2026 Mar 14]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06852222."},{"key":"e_1_3_3_66_1","unstructured":"Janssen Research & Development LLC. A study of JNJ-75276617 in combination with conventional chemotherapy for pediatric and young adult participants with relapsed\/refractory acute leukemias; 2026 [cited 2026 Jan 5]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05521087."},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01632-8"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-202042"},{"key":"e_1_3_3_69_1","volume-title":"Bethesda (MD): ClinicalTrials.gov","author":"Morris S.","unstructured":"Morris S. Study of BMF-219, a covalent menin inhibitor in adult patients with AML, ALL (with KMT2A\/MLL1r, NPM1 mutations), DLBCL, MM, and CLL\/SLL [Internet]. Bethesda (MD): ClinicalTrials.gov. 2021 [cited 2025 Jan 13]. Available from: NCT05153330 study record"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-025-02678-4"},{"key":"e_1_3_3_71_1","unstructured":"Borate U. SNDX-5613 and gilteritinib for the treatment of relapsed or refractory FLT3-mutated acute myeloid leukemia and concurrent MLL-rearrangement or NPM1 mutation; 2026 [cited 2026 Jan 5]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT06222580."},{"key":"e_1_3_3_72_1","unstructured":"Issa GA. Multi-site break through cancer trial: phase II study investigating dual inhibition of BCL2 and menin in AML MRD using the combination of venetoclax and revumenib; 2026 [cited 2026 Jan 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06284486."},{"key":"e_1_3_3_73_1","unstructured":"Huls G. Revumenib in combination with azacitidine\u2009+\u2009venetoclax in patients NPM1-mutated or KMT2A-rearranged AML; 2026 [cited 2026 Jan 7]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT06652438."},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-198218"},{"key":"e_1_3_3_75_1","unstructured":"Kura Oncology Inc. Safety and tolerability of ziftomenib combinations in patients with relapsed\/refractory acute myeloid leukemia; 2026 [cited 2026 Jan 8]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT06001788."},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-194827"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01757-4"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2025.06.002"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21873"},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2022.02.004"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025018178"},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000001185"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021359"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.3390\/genes15091231"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-024-00262-x"},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967412.62331.23"},{"key":"e_1_3_3_87_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05755-9"},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.1182\/hem.V20.5.2023510"},{"key":"e_1_3_3_89_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-208887"},{"key":"e_1_3_3_90_1","doi-asserted-by":"publisher","DOI":"10.3390\/computation12010003"},{"key":"e_1_3_3_91_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023644"},{"key":"e_1_3_3_92_1","doi-asserted-by":"publisher","DOI":"10.1101\/2025.03.24.644993"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2026.2674818","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/10428194.2026.2674818","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2026.2674818","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:24:29Z","timestamp":1785759869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2026.2674818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":91,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,7,29]]}},"alternative-id":["10.1080\/10428194.2026.2674818"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2026.2674818","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-02-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}